SBHM.Y Aktienübersicht Sino Biopharmaceutical Limited, eine Investment-Holdinggesellschaft, ist ein pharmazeutisches Forschungs- und Entwicklungskonglomerat in der Volksrepublik China. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
Sino Biopharmaceutical Limited Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Sino Biopharmaceutical Historische Aktienkurse Aktueller Aktienkurs HK$7.25 52-Wochen-Hoch HK$9.65 52-Wochen-Tief HK$6.69 Beta 0.68 1 Monat Veränderung -13.02% 3 Monate Veränderung n/a 1 Jahr Veränderung -2.24% 3 Jahre Veränderung -47.80% 5 Jahre Veränderung -59.73% Veränderung seit IPO -14.64%
Aktuelle Nachrichten und Updates
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21 Weitere Updates anzeigen
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection in Combination with Chemotherapy Dec 27
Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma Dec 19
Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer Dec 18
Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection Dec 11
Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer Nov 27
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma Nov 21
Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States Nov 14
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Oct 21
Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO Sep 27
Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024 Sep 16
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma Aug 28
Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma Aug 01
Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024 Jul 31
Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule Jul 18
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma Jul 16
Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet Jul 15
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection Jun 25
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)" Jun 19 Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director Jun 06
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma May 24
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China May 10
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules May 01
Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024 Mar 29
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024 Mar 28
Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225" Mar 16
Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet Mar 13
Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 02
Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart Feb 28
Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion. Feb 08
Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553) Jan 23
Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain Dec 28
Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma Dec 22
Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722 Dec 12
Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038 Dec 05
An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million. Nov 10
Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug Oct 17
An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 12
An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million. Oct 11
Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA Sep 26
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023 Aug 26
Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 03
Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms Jul 01
Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine May 24
Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection) May 11
Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation Feb 11
Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer Jan 14
Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203" Dec 10 Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022 Aug 24
Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022 Aug 12 Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022
Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule Jun 28
Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial Jun 15
Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139" May 24
Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial Apr 21
Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication Apr 20
Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE Apr 09
Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China Apr 08 Sino Biopharmaceutical Limited, Annual General Meeting, Jun 06, 2022
Sino Biopharmaceutical Limited Announces Category I Anti-Tumour Innovative Medicine FHND5071 Obtained Approval for Clinical Trial Mar 30
Sino Biopharmaceutical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022 Mar 03
Sino Biopharmaceutical Limited Announces Approval of "Adalimumab Solution for Injection" for Marketing Jan 22
Sino Biopharmaceutical Limited Announces Sitagliptin Phosphate and Metformin Hydrochloride Sustained-Release Tablets Obtained Drug Registration Certificate Granted by National Medical Products Administration Jan 12
Sino Biopharmaceutical Limited's TCR1672 Obtains Approval for Clinical Trial Dec 22
Akeso, Inc. and Sino Biopharmaceutical Limited Announces Penpulimab Monoclonal Antibody Marketing Approval in China Aug 08
Sino Biopharmaceutical Limited Announces "Dexmedetomidine Hydrochloride Injection" Obtains Drug Registration Certificate Jul 16
Sino Biopharmaceutical Limited Announces That the Phase Iii Clinical Trial Results of "Anlotinib Hydrochloride Capsules Jun 09
Sino Biopharmaceutical Limited Announces "Tolvaptan Tablets" Obtains Drug Registration Certificate Jun 02
Sino Biopharmaceutical Limited Announces "Sunitinib Malate Capsules" Obtains Drug Registration Certificate May 29 Sino Biopharmaceutical Limited Declares Dividend for the Three Months Ended 31 March, 2021, Payable on 12 July, 2021
Sino Biopharmaceutical Limited Announces "Decitabine for Injection" Passes Consistency Evaluation Mar 14
Sino Biopharmaceutical Limited Announces That the "Fosaprepitant Dimeglumine for Injection", A Drug Developed by the Group Used for the Prevention of Nausea and Vomiting Caused by Chemotherapy, Has Obtained Approval of Abbreviated New Drug Application from the United States Food and Drug Administration Mar 10
Sino Biopharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 23, 2021 Mar 02 Akeso, Inc. and Sino Biopharmaceutical Limited Announce the Interim Analysis of the Phase III Clinical Trial of Penpulimab
Sino Biopharmaceutical Limited Announces Alfacalcidol Soft Capsule Obtains the Notice of Approval of Supplemental Application on Pharmaceutical Product Issued by the National Medical Products Administration of the People's Republic of China Feb 11 Sino Biopharmaceutical Limited Announces "Esomeprazole Magnesium Enteric-Coated Capsules" Obtains Drug Registration Certificate
Sino Biopharmaceutical Limited Announces Passing of Consistency Evaluation for Bortezomib for Injection Jan 24
Akeso, Inc. and Sino Biopharmaceutical Limited Announces Latest Study of Penpulimab Monoclonal Antibody (PD-1) in Combination with Anlotinib for 1L Advanced Hepatocellular Carcinoma Jan 22
Sino Biopharmaceutical Limited Announces Passing of Consistency Evaluation for "Linezolid and Glucose Injection" Jan 09 Sino Biopharmaceutical Limited Obtains Drug Registration Certificate for Afatinib Dimaleate Tablets
Sino Biopharmaceutical Limited Appoints Li Kwok Tung Donald as an Independent Non-Executive Director and a Member of the Audit Committee and Nomination Committee Jan 01
Sino Biopharmaceutical Limited's Digestive System Medicine Pantoprazole Sodium for Injection Obtains the Notice of Approval of Supplemental Applications Issued by the National Medical Products Administration of the People's Republic of China Dec 03
Sino Biopharmaceutical Limited Announces Pomalidomide Capsules Obtains Drug Registration Certificate Nov 14
Sino Biopharmaceutical Limited to Report Q3, 2020 Results on Nov 30, 2020 Nov 03 Sino Biopharmaceutical Limited Announces Completion of Enrollment in Phase Iii Clinical Trial in Combination with Chemotherapy for 1L Metastatic Squamous Nsclc with Penpulimab
Sino Biopharmaceutical Limited Announces Management Changes Aug 22
Sino Biopharmaceutical Limited to Report First Half, 2020 Results on Aug 28, 2020 Aug 04 Aktionärsrenditen SBHM.Y US Pharmaceuticals US Markt 7D -1.4% 2.4% -0.8% 1Y -2.2% 4.3% 22.7%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: SBHM.Y unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 4.3% erzielte.
Rendite vs. Markt: SBHM.Y hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 22.7 erzielte.
Preisvolatilität Is SBHM.Y's price volatile compared to industry and market? SBHM.Y volatility SBHM.Y Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.3% Market Average Movement 6.4% 10% most volatile stocks in US Market 18.7% 10% least volatile stocks in US Market 3.2%
Stabiler Aktienkurs: Der Aktienkurs von SBHM.Y war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: Unzureichende Daten , um die Volatilitätsveränderung von SBHM.Y im vergangenen Jahr zu bestimmen.
Über das Unternehmen Sino Biopharmaceutical Limited, eine Investment-Holding, ist ein pharmazeutisches Konglomerat für Forschung und Entwicklung in der Volksrepublik China. Das Unternehmen ist in drei Segmenten tätig: Modernisierte chinesische Arzneimittel und chemische Arzneimittel, Investitionen und Sonstige. Das Unternehmen bietet Onkologie-Medikamente an, darunter Anlotinib-Hydrochlorid-Kapseln unter der Marke Focus V, Penpulimab-Injektion unter der Marke Annike, Efbemalenograstin alfa-Injektion unter der Marke Yilishu, Pomalidomid-Kapseln unter der Marke Anyue, Bevacizumab-Injektion unter der Marke Anbeisi, Rituximab-Injektion unter der Marke Delituo und Trastuzumab zur Injektion unter der Marke Saituo; Medikamente zur Behandlung von Lebererkrankungen, wie Magnesium-Isoglycyrrhizinat-Injektion unter der Marke Tianqing Ganmei und Entecavir-Dispersions-Tabletten unter der Marke Runzhong; und Medikamente zur Behandlung von Atemwegserkrankungen, wie Budesonid-Suspension zur Inhalation unter der Marke Tianqing suchang und Colistimethat-Natrium zur Injektion unter der Marke Tianyun.
Mehr anzeigen Sino Biopharmaceutical Limited's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Sino Biopharmaceutical im Vergleich zum Marktanteil des Unternehmens? SBHM.Y grundlegende Statistiken Marktanteil US$6.58b Gewinn(TTM ) US$295.43m Umsatz(TTM ) US$3.83b
22.3x Kurs-Gewinn-Verhältnis
1.7x Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) SBHM.Y Gewinn- und Verlustrechnung (TTM ) Einnahmen CN¥27.79b Kosten der Einnahmen CN¥5.23b Bruttogewinn CN¥22.56b Sonstige Ausgaben CN¥20.41b Umsatz CN¥2.14b
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) 0.12 Bruttomarge 81.16% Nettogewinnspanne 7.71% Schulden/Eigenkapital-Verhältnis 22.6%
Wie hat sich SBHM.Y auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden
2.1% Aktuelle Dividendenrendite
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/02/02 02:53 Aktienkurs zum Tagesende 2025/01/29 00:00 Gewinne 2024/06/30 Jährliche Einnahmen 2023/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .
Analysten-Quellen Sino Biopharmaceutical Limited wird von 51 Analysten beobachtet. 24 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Ling Zhang BNP Paribas Securities (Asia) Justin Liu BNP Paribas Securities (Asia) Sharon Shi BOCI Research Ltd.
48 weitere Analysten anzeigen 
